• Phase III trial results published in The Lancet Child & Adolescent Health demonstrate ziresovir is the first RSV-targeted antiviral to show significant clinical efficacy in hospitalized infants under 6 months of age.
• Treatment with ziresovir led to a 54.5% greater reduction in bronchiolitis symptoms and significantly faster viral clearance compared to placebo, with improvements in respiratory rate, wheezing, and chest retractions.
• Two-year follow-up data revealed long-term respiratory benefits, including 3.6 times lower incidence of recurrent wheezing and reduced asthma rates, suggesting early antiviral intervention may prevent chronic respiratory conditions.